Switch theme
Sign up to access all valuation multiples
Finemedix Co Ltd is engaged in manufacturing of other medical and surgical equipment and orthopedic appliances. The company is engaged in production of endoscopic surgical instruments and domestically produced functionally endoscopic incisions, snares, etc. The company is supplying its products to several university hospitals, large hospitals, and clinics in Korea, and are continuously planning and developing products that actively reflect the ideas of developed domestic medical staff and voices from the field. In addition, the company is preparing for overseas exports by obtaining CE and FDA certifications and is emerging as a specialized medical device company.
2009
n/a
Last FY Revenue $7.2M
Last FY EBITDA $0.7M
$29.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Finemedix achieved revenue of $7.2M and an EBITDA of $0.7M.
Finemedix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Finemedix valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $7.2M | XXX | XXX | XXX |
| Gross Profit | XXX | $4.1M | XXX | XXX | XXX |
| Gross Margin | XXX | 57% | XXX | XXX | XXX |
| EBITDA | XXX | $0.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 9% | XXX | XXX | XXX |
| EBIT | XXX | -$21K | XXX | XXX | XXX |
| EBIT Margin | XXX | 0% | XXX | XXX | XXX |
| Net Profit | XXX | -$18K | XXX | XXX | XXX |
| Net Margin | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Finemedix's stock price is KRW 8280 (or $6).
Finemedix has current market cap of KRW 45.0B (or $32.7M), and EV of KRW 40.4B (or $29.4M).
See Finemedix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.4M | $32.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Finemedix has market cap of $32.7M and EV of $29.4M.
Finemedix's trades at 4.1x EV/Revenue multiple, and 44.6x EV/EBITDA.
Equity research analysts estimate Finemedix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Finemedix's P/E ratio is not available.
See valuation multiples for Finemedix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.7M | XXX | $32.7M | XXX | XXX | XXX |
| EV (current) | $29.4M | XXX | $29.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 44.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1383.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1861.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -95.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFinemedix's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Finemedix's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Finemedix's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Finemedix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Finemedix acquired XXX companies to date.
Last acquisition by Finemedix was XXXXXXXX, XXXXX XXXXX XXXXXX . Finemedix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Finemedix founded? | Finemedix was founded in 2009. |
| Where is Finemedix headquartered? | Finemedix is headquartered in South Korea. |
| Is Finemedix publicy listed? | Yes, Finemedix is a public company listed on KRX. |
| What is the stock symbol of Finemedix? | Finemedix trades under 387570 ticker. |
| When did Finemedix go public? | Finemedix went public in 2024. |
| Who are competitors of Finemedix? | Similar companies to Finemedix include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Finemedix? | Finemedix's current market cap is $32.7M |
| Is Finemedix profitable? | Yes, Finemedix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
